SG10201811729PA - Membrane-penetrating peptides to enhance transfection and compositions and methods for using same - Google Patents

Membrane-penetrating peptides to enhance transfection and compositions and methods for using same

Info

Publication number
SG10201811729PA
SG10201811729PA SG10201811729PA SG10201811729PA SG10201811729PA SG 10201811729P A SG10201811729P A SG 10201811729PA SG 10201811729P A SG10201811729P A SG 10201811729PA SG 10201811729P A SG10201811729P A SG 10201811729PA SG 10201811729P A SG10201811729P A SG 10201811729PA
Authority
SG
Singapore
Prior art keywords
cargo
membrane
compositions
methods
peptides
Prior art date
Application number
SG10201811729PA
Inventor
Mollerat Du Jeu Xavier De
Original Assignee
Life Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Technologies Corp filed Critical Life Technologies Corp
Publication of SG10201811729PA publication Critical patent/SG10201811729PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

MEMBRANE-PENETRATING PEPTIDES TO ENHANCE TRANSFECTION AND COMPOSITIONS AND METHODS FOR USING SAME The present invention is directed to non-naturally occurring peptides containing a membrane-penetrating amino acid sequence and further at least one polycationic moiety or peptide sequence. The peptides are suitable for use in delivery a cargo to the interior of a cell. Suit - able cargo includes nucleic acid molecules (including DNA, RNA or PNA), polypeptides, or other biologically active molecules. The present invention is further directed to transfection complexes containing the non-naturally occurring peptides of the present invention in non-covalent association with at least one cationic lipid and a cargo to be delivered to the interior of a cell. The invention further relates to methods for the preparation and use of the non-naturally occurring peptides for the formation of transfection complexes and the delivery of a cargo to the interior of a cell in culture, an animal or a human. The invention also relates to compositions and kits useful for transfecting cells. [Fig. 9B]
SG10201811729PA 2013-12-12 2014-12-12 Membrane-penetrating peptides to enhance transfection and compositions and methods for using same SG10201811729PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361915429P 2013-12-12 2013-12-12

Publications (1)

Publication Number Publication Date
SG10201811729PA true SG10201811729PA (en) 2019-02-27

Family

ID=52273587

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201811729PA SG10201811729PA (en) 2013-12-12 2014-12-12 Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
SG11201604697TA SG11201604697TA (en) 2013-12-12 2014-12-12 Membrane-penetrating peptides to enhance transfection and compositions and methods for using same

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201604697TA SG11201604697TA (en) 2013-12-12 2014-12-12 Membrane-penetrating peptides to enhance transfection and compositions and methods for using same

Country Status (11)

Country Link
US (3) US9856496B2 (en)
EP (2) EP3079723B1 (en)
JP (2) JP6912887B2 (en)
KR (1) KR102532559B1 (en)
CN (2) CN106456793B (en)
AU (2) AU2014361806B2 (en)
BR (1) BR112016013516A8 (en)
CA (1) CA2933561A1 (en)
ES (1) ES2808866T3 (en)
SG (2) SG10201811729PA (en)
WO (1) WO2015089487A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3051089C (en) 2012-05-02 2022-04-12 Life Technologies Corporation High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers
CN104583957B (en) 2012-06-15 2018-08-10 英特尔公司 With the speculative instructions sequence without the rearrangement for disambiguating out of order load store queue
CN104583943B (en) 2012-06-15 2018-06-08 英特尔公司 Possess the virtual load storage queue of the dynamic assignment window with distributed frame
EP2862084A4 (en) 2012-06-15 2016-11-30 Soft Machines Inc A method and system for implementing recovery from speculative forwarding miss-predictions/errors resulting from load store reordering and optimization
WO2013188754A1 (en) 2012-06-15 2013-12-19 Soft Machines, Inc. A disambiguation-free out of order load store queue
KR101826399B1 (en) 2012-06-15 2018-02-06 인텔 코포레이션 An instruction definition to implement load store reordering and optimization
KR101996351B1 (en) 2012-06-15 2019-07-05 인텔 코포레이션 A virtual load store queue having a dynamic dispatch window with a unified structure
US9856496B2 (en) 2013-12-12 2018-01-02 Life Technologies Corporation Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
JP7199809B2 (en) 2015-02-13 2023-01-06 ファクター バイオサイエンス インコーポレイテッド Nucleic acid product and its administration method
JP6865207B2 (en) 2015-07-13 2021-04-28 ライフ テクノロジーズ コーポレーション Systems and methods for improved transient protein expression in CHO cells
IL264439B1 (en) 2016-08-17 2024-04-01 Factor Bioscience Inc non-viral, cell-free composition comprising a synthetic messenger RNA (MRNA) encoding a gene-editing protein for use in treating cancer, and a synthetic RNA encoding a gene-editing protein for use in treatment
CN109890959A (en) * 2016-09-30 2019-06-14 生命技术公司 The serum free suspension liquid system of lentivirus production
AU2018337737A1 (en) 2017-09-19 2020-04-02 Cannametrix, Llc Cell-based assay for quantifying the potency and efficacy of cannabinoids and/or terpenoids, and methods of use thereof
GB201821269D0 (en) 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
EP3927723A1 (en) * 2019-02-22 2021-12-29 Life Technologies Corporation Suspension system for adeno associated virus production
KR102261371B1 (en) * 2019-04-01 2021-06-08 한양대학교 산학협력단 Anticancer peptide for targeting CP2c
WO2020204605A1 (en) * 2019-04-01 2020-10-08 한양대학교 산학협력단 Cp2c-targeting peptide-based anticancer agent
EP4010027A1 (en) * 2019-08-05 2022-06-15 PolyPlus Transfection Compositions for transfecting a nucleic acid molecule into a cell comprising heterocyclic compounds grafted to a cationic polymer, and their applications
KR102515464B1 (en) * 2020-04-29 2023-03-28 연세대학교 원주산학협력단 Cytotoxic mitigating membrane permeable peptides for improving nucleic acid or genetransfection efficiency and use thereof
EP4368176A1 (en) 2021-07-08 2024-05-15 Nippon Shinyaku Co., Ltd. Nephrotoxicity reducing agent
TW202317147A (en) 2021-07-08 2023-05-01 日商日本新藥股份有限公司 Precipitation inhibitor
CA3225454A1 (en) 2021-07-08 2023-01-12 Nippon Shinyaku Co., Ltd. Nephrotoxicity reducing agent
CN113563429A (en) * 2021-07-19 2021-10-29 天津大学 Nucleic acid delivery system based on alkylated polypeptide, preparation method and application
WO2023014909A1 (en) * 2021-08-04 2023-02-09 AJK Biopharmaceutical, LLC Amphiphilic peptides for nucleic acid and protein delivery
CN114106095B (en) * 2021-11-11 2023-06-09 华南理工大学 Cell autophagy detection molecular probe based on aggregation-induced emission principle, and preparation method and application thereof
WO2024006937A1 (en) 2022-06-30 2024-01-04 Life Technologies Corporation Lipid compositions for in vivo delivery
GB202211597D0 (en) 2022-08-09 2022-09-21 Nchain Licensing Ag Computer-implemented method and system
CN115947817A (en) * 2023-02-22 2023-04-11 广州庆毅生物医药科技有限公司 Tumor-related polypeptide and preparation method and application thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
FR2645866B1 (en) 1989-04-17 1991-07-05 Centre Nat Rech Scient NEW LIPOPOLYAMINES, THEIR PREPARATION AND THEIR USE
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5316948A (en) 1992-09-04 1994-05-31 Life Technologies, Inc. N4 -methyl-2'-deoxycytidine 5'-triphosphate and its use in polymerase-catalyzed nucleic acid syntheses
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6075012A (en) 1994-02-11 2000-06-13 Life Technologies, Inc. Reagents for intracellular delivery of macromolecules
US5627159A (en) 1994-10-27 1997-05-06 Life Technologies, Inc. Enhancement of lipid cationic transfections in the presence of serum
EP0874910A4 (en) 1995-06-07 1999-04-21 Life Technologies Inc Peptide-enhanced cationic lipid transfections
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
SE9804614A0 (en) 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof
EP1829856A3 (en) 1998-11-12 2009-02-25 Invitrogen Corporation Transfection reagents
US6664040B2 (en) 2000-05-23 2003-12-16 The Regents Of The University Of California Compositions and methods for delivery of a molecule into a cell
AU8466501A (en) 2000-07-21 2002-02-05 Essentia Biosystems Inc Multi-component biological transport systems
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
GB0106315D0 (en) * 2001-03-14 2001-05-02 Ich Productions Ltd Transfection complexes
JP2006517790A (en) 2003-01-09 2006-08-03 インヴィトロジェン コーポレーション Cellular delivery and activation of polypeptide-nucleic acid complexes
EP1628647A4 (en) 2003-05-22 2007-10-24 Molecular Transfer Inc Novel lipids for transfection of nucleic acids
WO2005016960A2 (en) * 2003-08-14 2005-02-24 Diatos Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
US20050288246A1 (en) * 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
EP1968643A2 (en) 2005-12-16 2008-09-17 Diatos Cell penetrating peptide conjugates for delivering of nucleic acids into a cell
MX2008008548A (en) 2005-12-30 2008-09-10 Evonik Roehm Gmbh Peptides useful as cell-penetrating peptides.
EP1998809B1 (en) 2006-03-30 2014-06-25 Drais Pharmaceuticals, Inc. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
CA2651389C (en) 2006-05-05 2017-04-25 Molecular Transfer, Inc. Novel reagents for transfection of eukaryotic cells
WO2008108505A1 (en) 2007-03-07 2008-09-12 Japan As Represented By President Of International Medical Center Of Japan Novel nuclear translocation peptide
EP2379577A4 (en) * 2008-12-23 2012-08-29 Vivoscript Inc Compositions and methods for re-programming cells without genetic modification
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011127210A1 (en) 2010-04-06 2011-10-13 Massachusetts Institute Of Technology Targeted delivery of nucleic acids
EP2576595B1 (en) * 2010-05-30 2016-12-21 The Governing Council Of The University Of Toronto Mitochondrial penetrating peptides as carriers for anticancer compounds
CN103096932B (en) 2010-06-14 2016-10-12 弗·哈夫曼-拉罗切有限公司 Cell-penetrating peptides and application thereof
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
WO2012068176A1 (en) 2010-11-15 2012-05-24 Life Technologies Corporation Amine-containing transfection reagents and methods for making and using same
CN102153629B (en) * 2011-01-20 2013-07-24 华中科技大学 Short peptide and application thereof
US8853145B2 (en) * 2011-11-14 2014-10-07 Carlos Witte-Hoffmann BLID; a novel protein domain for interaction with the Bcl-2 family of proteins
EP2825561A4 (en) * 2012-03-15 2016-03-09 Permeon Biolog Inc Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use
US9856496B2 (en) 2013-12-12 2018-01-02 Life Technologies Corporation Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
KR102476764B1 (en) * 2015-12-23 2022-12-14 에스케이하이닉스 주식회사 Isolation structure and method for manufacturing the same
US9926825B2 (en) 2016-04-19 2018-03-27 GM Global Technology Operations LLC Method and apparatus for exhaust purification for an internal combustion engine

Also Published As

Publication number Publication date
BR112016013516A8 (en) 2020-05-19
KR102532559B1 (en) 2023-05-16
JP2020015747A (en) 2020-01-30
AU2020202002A1 (en) 2020-04-09
WO2015089487A1 (en) 2015-06-18
CN106456793B (en) 2021-04-30
JP2017500856A (en) 2017-01-12
US20150211021A1 (en) 2015-07-30
AU2014361806A1 (en) 2016-07-28
CN106456793A (en) 2017-02-22
BR112016013516A2 (en) 2017-08-08
AU2014361806B2 (en) 2019-12-19
JP6985347B2 (en) 2021-12-22
US20180163231A1 (en) 2018-06-14
KR20160103024A (en) 2016-08-31
CN113105559A (en) 2021-07-13
US10760098B2 (en) 2020-09-01
EP3079723B1 (en) 2020-05-27
EP3756690A2 (en) 2020-12-30
ES2808866T3 (en) 2021-03-02
EP3079723A1 (en) 2016-10-19
EP3756690A3 (en) 2021-03-17
US9856496B2 (en) 2018-01-02
AU2020202002B2 (en) 2021-08-05
US20200392537A1 (en) 2020-12-17
CA2933561A1 (en) 2015-06-18
SG11201604697TA (en) 2016-07-28
JP6912887B2 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
SG10201811729PA (en) Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
Zuris et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo
EA201790968A1 (en) PEPTID-MEDIATED DELIVERY OF THE DIRECTED RNA ENDONUCLEASE IN CELLS
WO2010129023A3 (en) Supercharged proteins for cell penetration
MX2009013325A (en) Nanocarrier based plant transfection and transduction.
MX2013003681A (en) Engineered nucleic acids and methods of use thereof.
Zuris et al. Efficient delivery of genome-editing proteins in vitro and in vivo
IL192131A0 (en) Peptides useful as cell-penetrating peptides
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
EP2583976A3 (en) Peptide vaccines with SEQ ID NO: 210, 196, 202, 213, 214, 214 or 223 for cancers expressing tumor-associated antigens
WO2009134808A3 (en) Supercharged proteins for cell penetration
MX2015016588A (en) Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides.
RU2014110901A (en) PEPTIDE PARTICLES AND THEIR APPLICATION
IN2014CN04734A (en)
SG10201407944TA (en) Imp-3 oligopeptides and vaccines including the same
RU2013116447A (en) SYSTEMS AND METHODS OF DELIVERY OF BIOACTIVE PRODUCTS USING VEHICLE SEQUENCES ORIGINING FROM BACTERIAL TOXIN
WO2014070687A3 (en) Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells
MY180183A (en) Methods and compositions for preventing norleucine misincorporation into proteins
WO2023018990A9 (en) Lipids for nucleic acid delivery
IN2014DN09963A (en)
WO2015120542A8 (en) Hybrid proteins and uses thereof
WO2008150276A3 (en) Virus coated nanoparticles and uses thereof
EP2594638B1 (en) Method for introducing nucleic acid to cell and nucleic acid complex
WO2014006452A3 (en) Rapid alkalinization factor peptides for delivery of nucleic acid molecules into cells
RU2008153051A (en) METHOD FOR DIRECTED DELIVERY OF DNA TO TUMOR AND STEM CELLS